Exploring a new biomarker for Alzheimer's in individuals with Down Syndrome
Investigate the utility of APLP1 as an endosomal biomarker for Alzheimer's Disease in Down Syndrome
This study is looking at a protein called APLP1 to see if it can help us understand early signs of Alzheimer's disease in people with Down Syndrome, with the hope that it will lead to better treatments in the future.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10727134 on NIH RePORTER |
What this research studies
This research investigates the role of APLP1 as a potential biomarker for Alzheimer's disease specifically in individuals with Down Syndrome. It aims to identify and validate new biomarkers that reflect endosomal dysfunction, which is an early indicator of Alzheimer's pathology. By focusing on the cellular biology of Alzheimer's rather than just the traditional markers like amyloid plaques, this research could lead to more effective therapeutic interventions. The study involves proteomic screening and analysis of cerebrospinal fluid from mouse models to identify relevant biomarkers that could also be applicable to human patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with Down Syndrome who are at risk for developing Alzheimer's disease.
Not a fit: Patients without Down Syndrome or those who do not have a risk of Alzheimer's disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to earlier diagnosis and more targeted treatments for Alzheimer's disease in individuals with Down Syndrome.
How similar studies have performed: Previous research has shown promise in identifying biomarkers for Alzheimer's disease, but this specific approach focusing on endosomal dysfunction in Down Syndrome is relatively novel.
Where this research is happening
New York, United States
- Columbia University Health Sciences — New York, United States (Active)
Researchers
- Principal investigator: Alves Simoes Spassov, Sabrina — Columbia University Health Sciences
- Study coordinator: Alves Simoes Spassov, Sabrina
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.